Diltiazem for Rate Control in Atrial Fibrillation with HFpEF
Diltiazem is appropriate for rate control in atrial fibrillation in patients with HFpEF (LVEF >40%), but β-blockers should be considered first-line unless contraindicated. 1
Primary Recommendation
β-blockers or non-dihydropyridine calcium channel blockers (diltiazem or verapamil) are both recommended as first-line agents for AF rate control in patients with preserved ejection fraction (LVEF >40%). 2, 3 The 2025 AHA Guidelines explicitly state that "patients with heart failure with preserved ejection fraction may tolerate better nondihydropyridine calcium channel antagonists" compared to those with reduced ejection fraction. 1
Key Distinction: HFpEF vs HFrEF
The critical threshold is LVEF 40%:
- LVEF >40% (HFpEF): Both β-blockers and diltiazem are appropriate first-line options 2, 3
- LVEF ≤40% (HFrEF): β-blockers are strongly preferred; diltiazem should be avoided due to negative inotropic effects 4, 2
Clinical Evidence Supporting Diltiazem in HFpEF
The 2020 Canadian guidelines provide the most nuanced guidance, noting that while diltiazem carries theoretical concerns in heart failure, selective use has been safely employed in multiple studies. 2 A retrospective study by Jandali examined 162 patients with LVEF ≤50% (including 52 with LVEF ≤30%) and found no difference in rates of hypotension, ICU transfer, or mortality compared to patients with preserved EF. 2
Diltiazem demonstrates superior acute rate control compared to metoprolol, achieving heart rate control more quickly (13 vs 27 minutes) and producing greater HR reductions at 30 and 60 minutes. 1 This effectiveness advantage applies across the ejection fraction spectrum when used appropriately. 5
Practical Algorithm for Rate Control Agent Selection in AF with HFpEF
Step 1: Assess Hemodynamic Stability
- Hemodynamically unstable: Consider electrical cardioversion first
- Stable: Proceed to pharmacologic rate control
Step 2: Determine Ejection Fraction
- LVEF >40%: Both β-blockers and diltiazem appropriate
- LVEF ≤40%: β-blockers preferred; avoid diltiazem unless specific circumstances (see below)
Step 3: Consider Comorbidities
- Acute coronary syndrome: β-blockers are the agent of choice 2
- Decompensated heart failure: Amiodarone or digoxin preferred over diltiazem 2, 3
- Severe COPD/asthma: Diltiazem preferred over β-blockers (though β-blockers are safer in COPD than historically believed) 1
- Hypotension: Avoid both; consider amiodarone or digoxin 2
Step 4: Dosing for Acute Rate Control
IV Diltiazem: 15-20 mg (0.25 mg/kg) over 2 minutes; may repeat 20-25 mg (0.35 mg/kg) in 15 minutes if needed; maintenance infusion 5-15 mg/h 6, 1
Target heart rate: <110 bpm at rest (lenient control is acceptable initially unless symptoms persist) 3
Critical Safety Considerations
When to Avoid Diltiazem Despite HFpEF
- Decompensated heart failure: Even with preserved EF, acute decompensation increases risk 4, 2
- Preexcitation syndromes (WPW): Absolute contraindication—may precipitate ventricular fibrillation 1
- Concurrent β-blocker use: Risk of profound bradycardia; use cautiously if combining 4
- Hypotension: Diltiazem causes vasodilation and may worsen hemodynamics 6, 2
Monitoring Requirements
- Blood pressure: Monitor for hypotension, particularly in first 30 minutes
- Heart rate: Watch for excessive bradycardia (<50 bpm)
- Clinical status: Assess for signs of worsening heart failure (increased dyspnea, oxygen requirements)
Recent data suggest diltiazem in reduced EF may increase acute kidney injury risk (10% vs 3.6% in normal EF), though this has not been specifically studied in HFpEF populations. 7
Emerging Evidence
A 2022 study in heart failure patients (including both HFrEF and HFpEF) found diltiazem achieved faster rate control than metoprolol with no differences in safety outcomes, including no increased risk of worsening heart failure. 5 However, a 2024 study showed increased clinical deterioration (33% vs 21%) when diltiazem was used despite clinical decision support warnings in patients with reduced EF. 8
The key distinction remains ejection fraction: HFpEF patients (LVEF >40%) tolerate diltiazem well, while those with LVEF ≤40% face increased risks. 1
Transition to Oral Therapy
Initiate oral rate control agents as soon as possible to maintain rate control and avoid rebound tachycardia as IV formulations wear off. 2 Oral diltiazem can be started while IV infusion continues, then IV discontinued once oral dosing is established.